Andere Sprachen Inozyme Pharma, Inc.

Aktien

A2P86D

US45790W1080

INZY

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 01.07.2024			% 5 Tage	% 1. Jan.
4.41 ^USD	-1.12%		-1.56%	+3.52%

30.05.	INOZYME PHARMA, INC. : Von Wells Fargo Securities zum Kaufen aufgerüstet	ZM
16.05.	Transcript : Inozyme Pharma, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:40 PM

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Inozyme Pharma Announces Presentation and Sponsored Symposium at the 11th International Conference on Children’s Bone Health (ICCBH)	21.06.
Inozyme Pharma to Present at the Jefferies Global Healthcare Conference	30.05.
Inozyme Pharma to Present Recently Announced Data from Phase 1/2 Trials of INZ-701 in Adults with ENPP1 Deficiency and ABCC6 Deficiency (PXE) at Upcoming Medical Conferences	23.05.
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference	08.05.
Inozyme Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07.05.
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights	07.05.
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	06.05.
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	03.05.
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency	08.04.
Inozyme Pharma, Inc. Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with Abcc6 Deficiency and ENPP1 Deficiency	08.04.
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.04.
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference	02.04.
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024	26.03.
Inozyme Pharma, Inc. to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency	26.03.
Inozyme Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	12.03.
Inozyme Pharma Reports Full Year 2023 Financial Results and Provides Business Highlights	12.03.
Inozyme Pharma to Participate in the TD Cowen 44th Annual Health Care Conference	26.02.
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	06.02.
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	05.12.
Inozyme Pharma to Participate in Upcoming Investor Conferences	09.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Inozyme Pharma, Inc.

Aktien

A2P86D

US45790W1080

INZY

Andere Sprachen

Filter